Omnivium Pharmaceuticals

Omnivium Pharmaceuticals is a UK-based biotechnology company specializing in the discovery and development of small molecule therapeutics for oncology. The company utilizes a proprietary fragment-based drug discovery (FBDD) platform to target challenging protein-protein interactions (PPIs) involved in cancer progression and DNA repair. Founded by world-leading scientists from the University of Cambridge and the University of Oxford, Omnivium focuses on "undruggable" targets to address significant unmet needs in cancer treatment. Their approach integrates structural biology, biophysics, and medicinal chemistry to design highly potent and selective inhibitors. The company's lead research efforts are centered on the DNA damage response pathway, specifically targeting the RAD51/BRCA2 interaction.